Anton P. Porsteinsson

University of Rochester Medical Center — United States

Medicine · Health Sciences

69h-index23.0kcitations326works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dementia and Cognitive Impairment Research(170), Alzheimer's disease research and treatments(106), Functional Brain Connectivity Studies(53), Schizophrenia research and treatment(27), Cholinesterase and Neurodegenerative Diseases(25)

Publications232 total

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials
CNS Drugs·2025Open Access
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial
Drugs·2025· 2 citedOpen Access
A US-based practitioner’s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer’s dementia – recommendations of an expert, multispecialty advisory panel
Postgraduate Medicine·2025· 1 cited
Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease
Alzheimer s & Dementia·2025· 6 citedOpen Access
Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders
International Psychogeriatrics·2025· 2 citedOpen Access
Escitalopram for agitation in Alzheimer’s dementia: a randomized controlled phase 3 trial
Nature Medicine·2025· 5 cited
Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer’s disease: A factor analysis
International Psychogeriatrics·2025· 2 citedOpen Access
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment
Nature Medicine·2025· 26 citedOpen Access
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial
The Lancet Neurology·2025· 14 cited
Fosgonimeton in mild-to-moderate Alzheimer's disease
Journal of Alzheimer s Disease Reports·2025Open Access
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
International Psychogeriatrics·2024· 1 citedOpen Access
Phase 3 Trial of Oral Anti‐Amyloid Agent ALZ‐801/Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Characteristics and Prevalence of Comorbid Cerebral Amyloid Angiopathy
Alzheimer s & Dementia·2024Open Access
Correlation between changes in apathy and cognition in Alzheimer’s disease associated apathy: analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Alzheimer s & Dementia·2024Open Access
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
Alzheimer s & Dementia·2024· 2 citedOpen Access
Escitalopram for Agitation in Alzheimer’s Dementia
Alzheimer s & Dementia·2024· 3 citedOpen Access
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2
International Psychogeriatrics·2024· 2 citedOpen Access
FC16: Timing and Duration of Adverse Events During Treatment of Agitation in Alzheimer’s Dementia with Brexpiprazole: Pooled Results From Three Phase 3 Trials
International Psychogeriatrics·2024Open Access
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease
Journal of the American Medical Directors Association·2024· 7 cited
Correction: Polygenic effects on the risk of Alzheimer’s disease in the Japanese population
Alzheimer s Research & Therapy·2024Open Access
APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in <i>APOE</i> ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics
Alzheimer s & Dementia Translational Research & Clinical Interventions·2024· 17 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Constantine G. Lyketsos(13), Jacobo Mintzer(12), Lon S. Schneider(11), Paul B. Rosenberg(10), Pierre N. Tariot(9), Lawrence S. Honig(8), Lea T. Drye(8), Cynthia A. Munro(8), Daniel Weintraub(8), John C. Morris(8), Marwan N. Sabbagh(7), Constantine Frangakis(7), Stephen Salloway(6), Peter V. Rabins(6), David Shade(6), William J. Jagust(6), John Q. Trojanowki(6), Arthur W. Toga(6), Laurel Beckett(6), Sonia Pawluczyk(6)